Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Oxyntomodulin peptide analogue

A technology of oxyntomodulatory peptides and analogues, applied in the direction of hormone peptides, specific peptides, drug combinations, etc., to achieve the effect of reducing side effects and improving weight

Active Publication Date: 2014-11-05
ELI LILLY & CO
View PDF13 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Furthermore, the intrinsic GcgR agonist activity of OXM is a risk factor for negatively affecting glycemic control

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oxyntomodulin peptide analogue
  • Oxyntomodulin peptide analogue
  • Oxyntomodulin peptide analogue

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0095] Example 1: Peptide Synthesis

[0096] Peptide analogues of SEQ ID NO: 1 and SEQ ID NO: 2 according to the present invention were generated by solid peptide synthesis on a Protein Technologies Inc. Symphony or Applied Biosystems 433A automated peptide synthesizer. Synthesis was performed on Fmoc-Rink amide polystyrene resin (Rapp Polymere Tubingen, Germany) with a substitution rate of about 0.7 mmol / g. Synthesis was performed using the Fmoc backbone protecting group strategy. The amino acid side chain derivatives used are: Arg(Pbf), Asn(Trt), Asp(OtBu), Cys(Trt), Gln(Trt), Glu(OtBu), His(Trt), Lys(Boc), Ser (OtBu), Thr(OtBu), Trp(Boc) and Tyr(OtBu). Amino acids activated by diisopropylcarbodiimide (DIC) and hydroxybenzotriazole (HOBt) in dimethylformamide (DMF) or N-methylpyrrolidone (NMP) (1:1:1 molar ratio) about 10 equivalents to perform the coupling. Couplings were performed at room temperature for 45-90 minutes.

[0097]Containing trifluoroacetic acid (TFA): tr...

Embodiment 2

[0098] Example 2: Pegylation of a peptide containing 2 Cys residues by mPEG-MAL-20kDa

[0099] The lyophilized peptide analog (SEQ ID NO: 2) produced according to Example 1 was weighed out (typically 30-50 mg). 2.1 molar equivalents of mPEG-20 kDa maleimide (CH3O(CH2CH2O)n-(CH2)3NHCO(CH2)2-maleimide) (NOF Sunbright ME-200MA) were weighed out and combined with the peptide. The reaction was dissolved in a 50 / 50 (v / v) water / acetonitrile mixture to a peptide concentration of approximately 20 mg / mL. The peptide analog solution was diluted 2-fold with 100 mM ammonium acetate, 10 mM ethylenediaminetetraacetic acid (EDTA), pH 7. The resulting mixture was then stirred at room temperature. The reaction mixture was monitored by analytical reverse-phase HPLC (analytical HPLC separation was performed on a Waters SymmetryShield C18, 3.5 micron, 4.6 mm i.d. x 10 cm column at 50° C. using a 2-stage linear AB gradient—5 minutes 0-30% B and Followed by 30 min 30-90% B, where A = 0.05% TFA / HO...

Embodiment 3

[0100] Example 3: Glucagon Receptor (hGcgR) Binding Assay

[0101] Glucagon receptor binding assay utilizing cloned human glucagon receptor (hGcgR) isolated from 293HEK membrane (Lok S, Kuijper JL, Jelinek LJ, Kramer JM, Whitmore TE, Sprecher CA, Mathewes S, Grant FJ, Biggs SH, Rosenberg GB, et al. Gene 140(2), 203-209 (1994)). The hGlucR cDNA was subcloned into the expression plasmid phD (Trans-activated expression of fully gamma-carboxylated recombinant human protein C, an antithrombotic factor. Grinnell, B.W., Berg, D.T., Walls, J. and Yan, S.B. Bio / Technology 5: 1189-1192 (1987)). This plasmid DNA was transfected into 293HEK cells and selected with 200 μg / ml hygromycin.

[0102] Crude plasma membranes were prepared using cells from suspension culture. Cells were lysed on ice in hypotonic buffer containing 25 mM Tris HCl, pH 7.5, 1 mM MgCl2, DNAse1, 20 ug / ml, and Roche complete inhibitor without EDTA. Homogenize the cell suspension with 25 strokes using a Teflon pestle ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides an Oxyntomodulin peptide analogue useful in the treatment of diabetes and / or obesity.

Description

technical field [0001] The present invention relates to Oxyntomodulin peptide analogs and pegylated derivatives thereof for use in the treatment of diabetes and / or obesity. Background technique [0002] Oxyntomodulin (OXM) is a 37 amino acid peptide hormone that, together with glucagon-like peptide 1 (GLP-1), is released from L cells of the small intestine in proportion to nutrient intake. It consists of the full-length 29-residue sequence of glucagon (Gcg) plus an 8-peptide extension at the C-terminus, and is the result of tissue-specific alternative splicing of preproglucagon. Endogenous OXM is rapidly degraded in vivo by dipeptidyl peptidase IV and other peptidases. [0003] The exact receptor for OXM remains unidentified. OXM binds and fully activates GLP-1 receptor (GLP-1R) and glucagon receptor (GcgR) in vitro, with similar potency on both receptors. [0004] OXM is involved in the regulation of food intake and body weight. Acute administration of OXM to normal wei...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/17A61K38/26C07K14/605A61P3/04A61P3/10
CPCA61K38/26A61K38/00C07K14/605A61K38/1709A61P3/00A61P3/04A61P7/12A61P3/10
Inventor J·阿尔西纳-费尔南德斯W·D·科恩
Owner ELI LILLY & CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com